Reactive thrombocytosis in children with upper urinary tract infections

2001 ◽  
Vol 90 (4) ◽  
pp. 448-449
Author(s):  
A Garoufi, K Voutsioti, H Tsapra, Th
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Upper Urinary Tract ◽  
Reactive Thrombocytosis ◽  
Tract Infections

Reactive thrombocytosis in children with upper urinary tract infections

2007 ◽  
Vol 90 (4) ◽  
pp. 448-449 ◽  
Author(s):  
A Garoufi ◽  
K Voutsioti ◽  
H Tsapra ◽  
Th Karpathios ◽  
PM Zeis
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Upper Urinary Tract ◽  
Reactive Thrombocytosis ◽  
Tract Infections

scholarly journals Antibacterial therapy for uncompleted upper urinary tract infections

2020 ◽  
Vol 9 (4) ◽  
pp. 37-40
Author(s):  
Adel S. Al-Shukri ◽  
Elena E. Zakharevich
Keyword(s):  
Antibacterial Activity ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Laboratory Tests ◽  
Upper Urinary Tract ◽  
Efficacy And Safety ◽  
Good Tolerance ◽  
High Antibacterial Activity ◽  
Tract Infections

To evaluate the efficacy and safety of the use of the drug Hileflox 750 (levofloxacin) in the treatment of uncomplicated infections of the upper urinary tract (pyelonephritis). 46 patients (9 men and 37 women) with uncomplicated pyelonephritis were observed. All patients were treated with Hileflox 750 mg orally once a day for 5 days. The drug showed high antibacterial activity, clinical efficacy and good tolerance. During follow-up for 6 months, not one patient showed abnormalities in laboratory tests, the development of complications or relapses of the disease. Conclusions: the results of the study showed the feasibility and effectiveness of the use of the drug Hayleflox 750 for the treatment of uncomplicated pyelonephritis in monotherapy.

Urinary Tract Infections in Women

2016 ◽  
Author(s):  
Arjun S. Chanmugam ◽  
Gino Scalabrini
Keyword(s):  
Urinary Tract ◽  
Pregnant Women ◽  
Urinary Tract Infections ◽  
Asymptomatic Bacteriuria ◽  
Upper Urinary Tract ◽  
Increased Risk ◽  
Resistance Patterns ◽  
Amoxicillin Clavulanic Acid ◽  
Tract Infections ◽  
Antibiotic Resistance Patterns

Urinary tract infections (UTIs) refer to a urine culture yielding a minimum of 100 to 10,000 bacteria units/mm of urine usually from a clean catch midstream sample. This can result from infection of the lower urinary tract involving the bladder (cystitis) or an infection of the upper urinary tract involving the kidneys (pyelonephritis). Uncomplicated UTIs occur in healthy, pre-menopausal, non-pregnant women with a normal urinary tract who have a high likelihood to respond favorably to treatment, but consider local antibiotic resistance patterns. Complicated UTIs occur in women with coexisting pathology, anatomical abnormality, underlying comorbidity, or immunocompromise. Untreated UTIs can progress to pyelonephritis and urosepsis. Asymptomatic bacteriuria for pregnant women can progress very quickly; pyelonephritis carries increased risk of perinatal and neonatal mortality. Pregnant patients should be treated with cephalexin, amoxicillin, or amoxicillin-clavulanic acid (avoiding fluoroquinolones).

Renal SPECT With Tc-99m DMSA in Children With Upper Urinary Tract Infections Using a Triple-Headed Gamma Camera

1997 ◽  
Vol 22 (12) ◽  
pp. 838-843 ◽  
Author(s):  
BRUNO BAGNI ◽  
PIERGIUSEPPE ORSOLON ◽  
ANDREA FATTORI ◽  
UGO PAOLO GUERRA
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Gamma Camera ◽  
Upper Urinary Tract ◽  
Tract Infections

Renal emergencies

2019 ◽  
pp. 289-326
Author(s):  
Punit S. Ramrakha ◽  
Kevin P. Moore ◽  
Amir H. Sam
Keyword(s):  
Acute Kidney Injury ◽  
Urinary Tract ◽  
Interstitial Nephritis ◽  
Urinary Tract Infections ◽  
Kidney Injury ◽  
Renal Stones ◽  
Upper Urinary Tract ◽  
Contrast Nephropathy ◽  
Cholesterol Embolism ◽  
Tract Infections

This chapter discusses renal emergencies, including acute kidney injury (AKI), anuria, interstitial nephritis, rhabdomyolysis, hepatorenal syndrome, acute upper urinary tract infections, renal colic and renal stones, haematuria, renovascular disease, cholesterol embolism, and contrast nephropathy.

Rantes –403g>a Functional Polymorphism and Upper Urinary Tract Infections in Children

2009 ◽  
Vol 5 ◽  
pp. S21
Author(s):  
Lina Artifoni ◽  
Elisa Benetti ◽  
Alejandra Stefanic ◽  
Susanna Negrisolo ◽  
Giovanni Montini ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Upper Urinary Tract ◽  
Functional Polymorphism ◽  
Tract Infections

Optimal bacterial colony counts for the diagnosis of upper urinary tract infections in infants

2019 ◽  
Vol 24 (3) ◽  
pp. 253-258
Author(s):  
Yuko Akagawa ◽  
Takahisa Kimata ◽  
Shohei Akagawa ◽  
Sadayuki Fujishiro ◽  
Shogo Kato ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Upper Urinary Tract ◽  
Bacterial Colony ◽  
Tract Infections

scholarly journals Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
George G. Zhanel ◽  
Michael A. Zhanel ◽  
James A. Karlowsky
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Urinary Tract Infections ◽  
Therapeutic Option ◽  
Multidrug Resistant ◽  
Upper Urinary Tract ◽  
Lower Urinary Tract Infection ◽  
Effective Therapeutic Option ◽  
Tract Infections

Oral fosfomycin is approved in Canada for the treatment of acute uncomplicated cystitis. Several studies have reported “off label” use of oral fosfomycin in the treatment of patients with complicated lower urinary tract infection (cLUTI). This review summarizes the available literature describing the use of oral fosfomycin in the treatment of patients with cLUTI. Collectively, these studies support the use of a regimen of 3 grams of oral fosfomycin administered once every 48 or 72 hours for a total of 3 doses for patients who have previously failed treatment with another agent, are infected with a multidrug-resistant (MDR) pathogen, or cannot tolerate first-line treatment due to intolerance or adverse effects. Additionally, a Phase 2/3 clinical trial, known as the ZEUS study, assessed the efficacy and safety of intravenous (IV) fosfomycin versus piperacillin-tazobactam in the treatment of patients with complicated upper urinary tract infection (cUUTI) or acute pyelonephritis (AP) including in patients with concomitant bacteremia. IV fosfomycin was reported to be noninferior to piperacillin-tazobactam in treating patients with cUUTI and AP; however, when outcomes were independently evaluated according to baseline diagnosis (i.e., cUUTI versus AP), IV fosfomycin was superior to piperacillin-tazobactam in the treatment of patients with cUUTI and demonstrated superior microbiological eradication rates, across all resistant phenotypes including extended-spectrum β-lactamase- (ESBL-) producing Escherichia coli and Klebsiella spp. and carbapenem-resistant (CRE), aminoglycoside-resistant, and MDR Gram-negative bacilli (primarily Enterobacterales). Based on the ZEUS study, IV fosfomycin dosed at 6 grams every 8 hours for 7 days (14 days in patients with concurrent bacteremia) appears to be a safe and effective therapeutic option in treating patients with upper urinary tract infections, particularly those with cUUTI caused by antimicrobial-resistant Enterobacterales.

Sign in / Sign up

Export Citation Format

Share Document